Isamu Okamoto

32.9k citations

383 papers · 13.9k indexed · 8 hit papers · h-index 61

Oncology top 0.1%
Pulmonary and Respiratory Medicine top 0.05%
Molecular Biology top 1%
Cancer Research top 0.5%
Surgery top 5%

Co-authors: Kazuhiko Nakagawa Masahiro Fukuoka Kazuto Nishio Nobuyuki Yamamoto Masayuki Takeda Yoichi Nakanishi Takashi Seto Kazuko Sakai
Topics: Lung Cancer Treatments and Mutations (275 papers)Lung Cancer Research Studies (128 papers)Colorectal Cancer Treatments and Studies (89 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Journal of Clinical Investigation Nature Communications Journal of Clinical Oncology
Partner nations: Japan United States South Korea

In The Last Decade

Isamu Okamoto

373 papers receiving 13.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

2012 592 citations Isamu Okamoto et al. Journal of Clinical Oncology profile →
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

2014 561 citations Makoto Nishio, Kazuhiko Nakagawa et al. profile →
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

2014 525 citations Koichi Azuma, Keiichi Ota et al. profile →
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

2018 511 citations Kazuhiko Nakagawa, Ki Hyeong Lee et al. Journal of Clinical Oncology profile →
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

2020 409 citations Isamu Okamoto et al. Journal of Thoracic Oncology profile →
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

2015 366 citations Keiichi Ota, Koichi Azuma et al. Clinical Cancer Research profile →
Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

2013 351 citations Shinya Ueda, Isamu Okamoto et al. Journal of Clinical Oncology profile →
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

2023 95 citations Isamu Okamoto, James Chih‐Hsin Yang et al. profile →

Peers

Countries citing papers authored by Isamu Okamoto

Since Specialization

Citations

This map shows the geographic impact of Isamu Okamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isamu Okamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isamu Okamoto more than expected).

Fields of papers citing papers by Isamu Okamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isamu Okamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isamu Okamoto. The network helps show where Isamu Okamoto may publish in the future.

Co-authorship network of co-authors of Isamu Okamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Isamu Okamoto. A scholar is included among the top collaborators of Isamu Okamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isamu Okamoto. Isamu Okamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy 2025 ·Cancer Research ·(unknown),(unknown),(unknown),Masaki Magari,(unknown),Youki Ueda,Takamasa Ishino,Joji Nagasaki,Tomohiro Fujiwara,Hidetaka Yamamoto,Hidetoshi Hayashi,Kota Tachibana,Joji Ishida,Yoshihiro Otani,(unknown),Shinichi Toyooka,Isamu Okamoto,Yosuke Togashi	2
2	Association Between Single Nucleotide Polymorphisms and Disease Susceptibility, Survival, and Acute Exacerbation in Idiopathic Pulmonary Fibrosis 2025 ·Respirology ·Kazuya Tsubouchi,Toyoshi Yanagihara,Fumiaki Kiyomi,Yuzo Yamamoto,(unknown),(unknown),(unknown),Shohei Takata,Hiroshi Ishii,Yasuhiko Kitasato,Masaki Okamoto,Satoru Kawakami,Kazuhiro Yatera,(unknown),Masaki Fujita,(unknown),Chikako Kiyohara,(unknown),Isamu Okamoto	0
3	AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts 2025 ·Cancer Science ·(unknown),(unknown),Yosuke Seto,Ken Uchibori,Makoto Nishio,Isamu Okamoto,Ryohei Katayama	1
4	MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC 2024 ·Journal of Thoracic Oncology ·(unknown),Ying Cheng,David R. Spigel,Jian Fang,Yuanbin Chen,Yoshitaka Zenke,Ki Hyeong Lee,Alejandro Navarro,(unknown),(unknown),Isamu Okamoto,Mustafa Özgüroğlu,(unknown),(unknown),Sayed M.S. Hashemi,Robert Turner,Helen Mann,(unknown),Haiyi Jiang,Suresh Senan	1
5	Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. 2023 ·Journal of Clinical Oncology ·James Chih‐Hsin Yang,(unknown),Jong Seok Lee,Yun Fan,Filippo de Marinis,Isamu Okamoto,Takako Inoue,(unknown),Zhang Li,Cheng‐Ta Yang,Emmanuel de la Mora Jimenez,Jianying Zhou,M. Pérol,Ki Hyeong Lee,David Vicente,Eiki Ichihara,Gregory J. Riely,Yiwen Luo,Niyati Bhagwati,Shun Lü	50
6	Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases 2023 ·Frontiers in Immunology ·(unknown),Toyoshi Yanagihara,(unknown),(unknown),Kunihiro Suzuki,Kazuya Tsubouchi,Daisuke Eto,Hiroyuki Ando,(unknown),Satoshi Ikegame,Yoshihiro Baba,Yoshinori Fukui,Isamu Okamoto	24
7	MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma 2023 ·Cancer Science ·(unknown),Yasuto Yoneshima,Koji Okamura,Toyoshi Yanagihara,Mikiko Hashisako,Takeshi Iwasaki,Naoki Haratake,(unknown),Keiichi Ota,Eiji Iwama,Tomoyoshi Takenaka,Kentaro Tanaka,Tomoharu Yoshizumi,Yoshinao Oda,Isamu Okamoto	4
8	Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors 2023 ·Lung Cancer ·(unknown),Hiroyuki Inoue,Yoshimasa Shiraishi,(unknown),(unknown),Hiroyuki Ando,(unknown),(unknown),Hiroaki Ogata,Koji Okamura,Shinichi Kimura,Tomohiro Ogawa,Keiichi Ota,Yasuto Yoneshima,Kentaro Tanaka,Naoki Hamada,Isamu Okamoto,Eiji Iwama	8
9	Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancerbreakdown → 2015 ·Clinical Cancer Research ·Keiichi Ota,Koichi Azuma,Akihiko Kawahara,Satoshi Hattori,Eiji Iwama,Junko Tanizaki,Taishi Harada,Koichiro Matsumoto,Koichi Takayama,Shinzo Takamori,Masayoshi Kage,Tomoaki Hoshino,Yoichi Nakanishi,Isamu Okamoto	366
10	Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer 2014 ·Clinical Cancer Research ·Takeshi Yoshida,Guolin Zhang,Matthew A. Smith,(unknown),Yun Bai,Jiannong Li,Bin Fang,John M. Koomen,Bhupendra Rawal,Kate Fisher,Y. Ann Chen,(unknown),(unknown),Haruka Yamaguchi,Kiyoko Shibata,Takafumi Okabe,Isamu Okamoto,Kazuhiko Nakagawa,Eric B. Haura	89
11	Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Junko Tanizaki,Isamu Okamoto,Takafumi Okabe,Kazuko Sakai,Kaoru Tanaka,Hidetoshi Hayashi,Hiroyasu Kaneda,Ken Takezawa,Kiyoko Kuwata,Haruka Yamaguchi,Erina Hatashita,Kazuto Nishio,Kazuhiko Nakagawa	126
12	Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification 2012 ·Molecular Cancer Therapeutics ·Wataru Okamoto,Isamu Okamoto,Tokuzo Arao,Kiyoko Kuwata,Erina Hatashita,Haruka Yamaguchi,Kazuko Sakai,Kazuyoshi Yanagihara,Kazuto Nishio,Kazuhiko Nakagawa	73
13	Overcoming Erlotinib Resistance in EGFR Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin 2011 ·Molecular Cancer Therapeutics ·Kunio Okamoto,Isamu Okamoto,Erina Hatashita,Kiyoko Kuwata,Haruka Yamaguchi,Aya Kita,Kentaro Yamanaka,Mayumi Ono,Kazuhiko Nakagawa	59
14	Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer 2011 ·Clinical Cancer Research ·Ken Takezawa,Isamu Okamoto,Kazuto Nishio,Pasi A. Jänne,Kazuhiko Nakagawa	115
15	Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors 2010 ·Molecular Cancer Therapeutics ·Isamu Okamoto,Hiroyasu Kaneda,Taroh Satoh,Wataru Okamoto,Masaki Miyazaki,Ryotaro Morinaga,Shinya Ueda,Masaaki Terashima,Asuka Tsuya,Akiko Sarashina,(unknown),Tokuzo Arao,Kazuto Nishio,R. Kaiser,Kazuhiko Nakagawa	79
16	Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor 2010 ·Molecular Cancer Therapeutics ·Ken Takezawa,Isamu Okamoto,Junko Tanizaki,Kiyoko Kuwata,Haruka Yamaguchi,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa	63
17	FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth 2010 ·Cancer Research ·Hiroyasu Kaneda,Tokuzo Arao,Kaoru Tanaka,Daisuke Tamura,Keiichi Aomatsu,Kanae Kudo,Kazuko Sakai,Marco A. De Velasco,Kunio Matsumoto,Yoshihiko Fujita,Yasuhide Yamada,Junji Tsurutani,Isamu Okamoto,Kazuhiko Nakagawa,Kazuto Nishio	157
18	Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition 2010 ·Molecular Cancer Therapeutics ·Wataru Okamoto,Isamu Okamoto,Takeshi Yoshida,Kunio Okamoto,Ken Takezawa,Erina Hatashita,Yuki Yamada,Kiyoko Kuwata,Tokuzo Arao,Kazuyoshi Yanagihara,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa	58
19	Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations 2010 ·Cancer Research ·Kunio Okamoto,Isamu Okamoto,Wataru Okamoto,Kaoru Tanaka,Ken Takezawa,Kiyoko Kuwata,Haruka Yamaguchi,Kazuto Nishio,Kazuhiko Nakagawa	75
20	Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells 2009 ·Clinical Cancer Research ·Tsutomu Iwasa,Isamu Okamoto,Minoru Suzuki,Erina Hatashita,Yuki Yamada,Masahiro Fukuoka,Koji Ono,Kazuhiko Nakagawa	51

About Isamu Okamoto

Isamu Okamoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 383 papers that have together received 13.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (275 papers), Lung Cancer Research Studies (128 papers) and Colorectal Cancer Treatments and Studies (89 papers). The work is most often cited by research in Oncology (9.5k citations), Pulmonary and Respiratory Medicine (9.4k citations) and Cancer Research (2.0k citations). Isamu Okamoto has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Kazuhiko Nakagawa, Masahiro Fukuoka, Kazuto Nishio, Nobuyuki Yamamoto, Masayuki Takeda, Yoichi Nakanishi, Takashi Seto, Kazuko Sakai, Eiji Iwama and Junko Tanizaki. Their work appears in journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact